Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by TNFRSF17 is a member of the TNF-receptor superfamily. Additionally we are shipping TNFRSF17 Proteins (38) and TNFRSF17 Kits (15) and many more products for this protein.
Showing 10 out of 108 products:
Human Monoclonal TNFRSF17 Primary Antibody for ELISA, WB - ABIN2658146
Mesin, Di Niro, Thompson, Lundin, Sollid: Long-lived plasma cells from human small intestine biopsies secrete immunoglobulins for many weeks in vitro. in Journal of immunology (Baltimore, Md. : 1950) 2011
Show all 4 references for ABIN2658146
Human Monoclonal TNFRSF17 Primary Antibody for FACS, IF - ABIN2662563
Rickert, Jellusova, Miletic: Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. in Immunological reviews 2011
Show all 4 references for ABIN2662563
Human Monoclonal TNFRSF17 Primary Antibody for ELISA (Capture), ELISPOT (Capture) - ABIN2664465
Coquery, Erickson: Regulatory roles of the tumor necrosis factor receptor BCMA. in Critical reviews in immunology 2012
Show all 4 references for ABIN2664465
Human Polyclonal TNFRSF17 Primary Antibody for EIA, WB - ABIN951253
Chae, Yu, Oh, Choi, Choi, Yang, Yun: Identification of single nucleotide polymorphisms in the TNFRSF17 gene and their association with gastrointestinal disorders. in Molecules and cells 2010
Show all 2 references for ABIN951253
shedding of BCMA by gamma-secretase controls plasma cells in the bone marrow and yields a potential biomarker for B-cell involvement in human autoimmune diseases
Data show significant differences in expression of tumour necrosis factor (show TNF Antibodies) family (BAFF (show TNFSF13B Antibodies)) receptors BAFF-R (show TNFRSF13C Antibodies), BCMA and TACI (show TNFRSF13B Antibodies) in patients with and without anti-Jo-1 or anti-Ro52 (show TRIM21 Antibodies)/anti-Ro60 (show TROVE2 Antibodies) autoantibodies.
High BCMA expression is associated with breast cancer.
BAFF (show TNFSF13B Antibodies) and APRIL as well as their cognate receptors (BCMA, TACI (show TNFRSF13B Antibodies)) correlate with glioma grade. (Meta-analysis)
The B cell maturation antigen (BCMA) is a tumor necrosis family receptor member that is predominantly expressed on terminally differentiated B cells and, upon binding to its ligands B cell activator of the TNF (show TNF Antibodies) family and a proliferation inducing ligand (show TNFSF13 Antibodies).
Activation of B cells through BCMA regulates spinal cord injury-induced autoimmunity via a proliferation-inducing ligand (show TNFSF13 Antibodies) (APRIL) and B-cell-activating factor (BAFF (show TNFSF13B Antibodies)).
Data indicate that MAGE3 (show MAGEA3 Antibodies), Survivin (show BIRC5 Antibodies) and B-cell maturation antigen (BCMA) mRNA-pulsed dendritic cells (DCs) are capable of stimulating tumor-associated antigens (TAA)-specific T-cell responses in multiple myeloma (MM) patients.
Data indicate that B-cell maturation antigen (BCMA) is a suitable target for chimeric antigen receptor (CAR)-expressing T cells, and adoptive transfer of anti-BCMA-CAR-expressing T cells is a promising new strategy for treating multiple myeloma.
B-cell maturation antigen (BCMA), an essential membrane protein for maintaining the survival of plasma cells, was identified as a glycoprotein exhibiting complex-type N-glycans at a single N-glycosylation site, asparagine 42.
the effect of APRIL is mediated via BCMA, which does not activate the classical NF-kappaB (show NFKB1 Antibodies) pathway, whereas it induces a novel signaling pathway, which involves JNK2 (show MAPK9 Antibodies) phosphorylation, FOXO3A (show FOXO3 Antibodies) activation, and GADD45 (show GADD45A Antibodies) transcription
high affinity antibody blocks the binding of the native ligands APRIL and BAFF (show TNFSF13B Antibodies) to BCMA. This finding is rationalized by the high resolution crystal structure of the Fab (show FANCB Antibodies) fragment in complex with the extracellular domain of BCMA
Elimination of B lymphocyte stimulator (show TNFSF13B Antibodies) receptor 3 (BR-3) and BCMA inhibits the development of SLE in NZM mice.
we have identified a novel role for BCMA to control excess BAFF (show TNFSF13B Antibodies) production in murine lupus through restraining the accumulation of BAFF (show TNFSF13B Antibodies)-producing neutrophils.
Heteromers consisting of one BAFF (show TNFSF13B Antibodies) and two APRIL bind to receptor TACI (show TNFRSF13B Antibodies), BCMA but not to BAFFR (show TNFRSF13C Antibodies).
BCMA is dispensable for the development of SLE in NZM mice. BAFF (show TNFSF13B Antibodies)-BCMA interactions contribute to SLE.
Study reveals that BCMA works to control B cell homeostasis and self-tolerance in systemic autoimmunity.
Blimp-1 (show PRDM1 Antibodies) is a positive regulator of the expression of BCMA gene in mouse plasma cells.
The 5'-flanking sequence from -820 to +145 bp of BCMA is of promoter activity.
A vital role of BCMA in bone marrow plasma cell survival.
B cell maturation antigen, the receptor for a proliferation-inducing ligand (show TNFSF13 Antibodies) and B cell-activating factor (show TNFSF13B Antibodies) of the TNF (show TNF Antibodies) family, induces antigen presentation in B cells.
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13B/TALL-1/BAFF), and to lead to NF-kappaB and MAPK8/JNK activation. This receptor also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation.
tumor necrosis factor receptor superfamily member 17
, tumor necrosis factor receptor superfamily, member 17
, B cell maturation antigen
, B-cell maturation factor
, B-cell maturation protein